97 related articles for article (PubMed ID: 8607034)
1. Antisense strategies in the treatment of leukemias.
Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
3. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells.
Opalinska JB; Machalinski B; Ratajczak J; Ratajczak MZ; Gewirtz AM
Clin Cancer Res; 2005 Jul; 11(13):4948-54. PubMed ID: 16000594
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
5. Myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
7. Antisense strategy in hematological malignancies.
Warzocha K
Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
[TBL] [Abstract][Full Text] [Related]
8. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
9. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
10. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B
J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009
[TBL] [Abstract][Full Text] [Related]
11. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
[TBL] [Abstract][Full Text] [Related]
12. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
13. [Antisense oligonucleotides with pharmacologic action].
Tauşer RG; Stoica O
Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):40-5. PubMed ID: 14755968
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
15. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
Kamitsuji Y; Kuroda J; Kimura S; Toyokuni S; Watanabe K; Ashihara E; Tanaka H; Yui Y; Watanabe M; Matsubara H; Mizushima Y; Hiraumi Y; Kawata E; Yoshikawa T; Maekawa T; Nakahata T; Adachi S
Cell Death Differ; 2008 Nov; 15(11):1712-22. PubMed ID: 18617896
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides.
Calabretta B; Skorski T; Zon G
Semin Cancer Biol; 1992 Dec; 3(6):391-8. PubMed ID: 1286160
[TBL] [Abstract][Full Text] [Related]
17. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
18. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
19. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications.
Gewirtz AM
Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543
[TBL] [Abstract][Full Text] [Related]
20. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
